Pyxis Oncology, Inc. (PYXS)
3.51
-0.38
(-9.77%)
USD |
NASDAQ |
Sep 09, 15:46
Pyxis Oncology Shareholders Equity (Quarterly) : 11.44M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 11.44M |
| March 31, 2026 | 31.27M |
| December 31, 2025 | 53.41M |
| September 30, 2025 | 68.78M |
| June 30, 2025 | 87.64M |
| March 31, 2025 | 103.10M |
| December 31, 2024 | 120.75M |
| September 30, 2024 | 153.68M |
| June 30, 2024 | 169.79M |
| March 31, 2024 | 184.16M |
| December 31, 2023 | 125.70M |
| September 30, 2023 | 137.95M |
| Date | Value |
|---|---|
| June 30, 2023 | 145.28M |
| March 31, 2023 | 152.16M |
| December 31, 2022 | 160.82M |
| September 30, 2022 | 188.75M |
| June 30, 2022 | 211.97M |
| March 31, 2022 | 233.51M |
| December 31, 2021 | 261.31M |
| September 30, 2021 | 122.58M |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | 6.297M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 54.92M |
| Total Liabilities (Quarterly) | 43.48M |
| Debt to Equity Ratio | 1.559 |
| Current Ratio | 1.337 |
| Net Debt Paydown Yield | 0.21% |